查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081920

隱球菌病治療市場：全球市場預測（按藥物類別、給藥途徑、患者類型、治療階段、最終用戶和分銷管道分類），2026-2032年

Cryptococcosis Treatment Market by Drug Class, Administration Route, Patient Type, Therapy Phase, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，隱球菌病治療市場將成長至 99.7 億美元，複合年成長率為 7.88%。

主要市場統計數據
基準年 2025 58.6億美元
預計年份：2026年 63.1億美元
預測年份：2032年 99.7億美元
複合年成長率 (%) 7.88%

隱球菌病的治療仍然是抗真菌藥物的首要市場。這是因為隱球菌性腦膜炎是晚期HIV感染疾病患者的主要死因之一，也是移植患者和其他免疫力缺乏族群的重要機會性感染疾病。已發表的全球疾病負擔估計表明，每年約有15.2萬例HIV感染者患有隱球菌性腦膜炎，其中約11.2萬人死亡。這凸顯了持續迫切需要更快的診斷、更安全的誘導治療以及可靠的抗真菌藥物供應。

對於製藥公司和抗真菌療法供應商而言，市場機會取決於臨床指南所規定的治療途徑。隱球菌病的標準治療方案包括誘導治療、強化治療和維持治療，主要使用Amphotericin B製劑、Flucytosine和Fluconazole。世界衛生組織（WHO）建議盡可能採用簡化的脂質奈米顆粒Amphotericin B療法。透過提高耐受性、增加Flucytosine和脂質奈米顆粒Amphotericin B的供應量、支持合理使用抗真菌藥物以及製定針對服務不足地區的藥物可及性計劃，有望獲得競爭優勢。

治療環境的變革性變化

隱球菌病的治療正從長期、高風險的住院治療轉向療程更短、循證的誘導治療，以提高患者的用藥依從性並減輕醫院的負擔。 AMBITION-cm 試驗表明，對於 HIV 相關隱球菌性腦膜炎，單次高劑量脂質Amphotericin B聯合Flucytosine和Fluconazole的治療方案，其療效不劣於傳統的 7 天Amphotericin B脫氧膽酸鹽方案，且嚴重不利事件發生率更低，這一發現正在影響全球隱球菌腦膜炎的治療策略。

人工智慧（AI）的累積影響

人工智慧 (AI) 正開始影響隱球菌病的治療，它能夠實現早期風險識別、最佳化臨床工作流程並更準確地預測抗真菌藥物的需求。 AI 驅動的電子健康記錄模型可識別 HIV 病情進展、CD4 細胞數量下降、移植後免疫抑制、骨髓惡性腫瘤、長期使用皮質類固醇或持續存在神經系統症狀的患者，從而提示需要進行隱球菌抗原檢測或緊急評估。雖然這些工具可以支援早期療育，但要廣泛應用，還需要進行臨床檢驗、管治、保護資料隱私和監測偏倚。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

亞太地區的情況各不相同。日本、澳洲和韓國的先進治療基礎設施較為完善，而印度和東南亞部分地區仍存在愛滋病晚期患者比例高、診斷延遲以及檢測機會不均等嚴重問題，導致大量醫療需求無法得到滿足。在印度，大規模的愛滋病治療網路、不斷擴充的三級醫療基礎設施以及日益增多的免疫力缺乏患者，使得隱球菌抗原檢測、Amphotericin B製劑、Flucytosine和Fluconazole的獲取對於改善治療效果至關重要。在北美，雖然已建立了完善的感染疾病網路、移植醫學系統、先進的診斷技術，並可獲得脂質奈米顆粒兩性Amphotericin B，但醫療保健的重點正日益轉向快速診斷和治療除愛滋病以外的其他免疫力缺乏功能低下患者，例如固態器官移植受者、癌症患者和接受生技藥品治療的患者。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，隱球菌病治療的需求與愛滋病防治計畫的成熟度、檢測設施的可及性、分發管道以及抗真菌藥物的採購能力密切相關。都市區分發機構通常比農村機構配備更完善的設備，能夠更好地進行誘導治療和監測兩性黴素相關毒性。在海灣合作理事會（GCC）國家，感染疾病、腫瘤和移植醫學等專科醫療服務正在不斷發展，因此對高品質抗真菌藥物、醫院治療方案以及先進醫療中心的綜合診斷方法提出了更高的需求。

主要隱球菌病治療市場的關鍵國家洞察

美國和加拿大構成了一個高價值的隱球菌病治療市場，這主要得益於先進的愛滋病治療、移植醫學、腫瘤學、生物免疫抑制療法、快速診斷以及感染疾病專家的普及。在這些市場中，毒性管理和真實世界安全性監測仍然至關重要。在墨西哥和巴西，在大規模公共衛生系統和愛滋病治療網路的支持下，治療需求正在不斷成長，但區域採購、醫院分發系統、Flucytosine的供應以及專家覆蓋範圍的差異可能會影響隱球菌性腦膜炎治療的一致性。

抗真菌藥物行業領導者使用的實用建議

產業供應商應優先確保可靠地獲得符合世界衛生組織指南的抗真菌藥物，特別是脂質奈米顆粒兩性Amphotericin B、Flucytosine和Fluconazole，並支持高感染負擔國家的本地採購模式。各機構可透過將藥物供應與臨床教育結合來提升自身競爭力，這些臨床教育涵蓋誘導治療、腎功能監測、電解質補充、血球減少症監測、治療順序安排、腰椎穿刺以及顱內壓增高管理等面向。

調查方法

本執行摘要是根據同儕審查的臨床證據、國際治療指南、公共衛生負擔評估、監管見解和既定感染疾病治療標準的三角檢驗。主要參考文獻包括世界衛生組織關於進行性HIV感染疾病和隱球菌病的指南、支持基於脂質奈米顆粒兩性Amphotericin B誘導療法的臨床實驗室證據，以及Amphotericin B、Flucytosine和Fluconazole的廣泛認可的治療原則。

結論

隨著脂質奈米顆粒Amphotericin B短期治療方案、隱球菌抗原篩檢和綜合HIV治療的出現，隱球菌病治療前景重新定義，治療市場正朝著更主導醫學的方向發展。儘管取得了進展，但在診斷、Flucytosine、兩性黴素製劑、腰椎穿刺服務和專業臨床管理資源有限的地區，可預防的死亡率仍然居高不下。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 隱球菌病治療市場：依藥物類別分類

  • 唑類藥物
    • Fluconazole
    • Posaconazole
    • Voriconazole
  • Flucytosine
  • Polyenes
    • 雙性殺黴素B脫氧膽酸鹽
    • 脂質奈米顆粒型Amphotericin B

第8章：隱球菌病治療市場：依給藥途徑分類

  • 靜脈
    • 中央靜脈
    • 周邊靜脈
  • 口服
    • 懸浮液
    • 藥片

第9章：隱球菌病治療市場：依患者類型分類

  • 愛滋病毒感染者
  • 未感染愛滋病毒的人
    • 免疫功能正常的患者
    • 移植患者

第10章：隱球菌病治療市場：依治療階段分類

  • 誘導治療
  • 整合療法
  • 維持治療

第11章 隱球菌病治療市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 居家醫療
  • 醫院

第12章 隱球菌病治療市場：依分銷管道分類

  • 離線
  • 線上

第13章：隱球菌病治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 隱球菌病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 隱球菌病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Gilead Sciences, Inc.
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xellia Pharmaceuticals ApS
  • Zydus Lifesciences Limited
Product Code: MRR-4316E4E894B8

The Cryptococcosis Treatment Market is projected to grow by USD 9.97 billion at a CAGR of 7.88% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.86 billion
Estimated Year [2026] USD 6.31 billion
Forecast Year [2032] USD 9.97 billion
CAGR (%) 7.88%

Cryptococcosis treatment remains a high-priority antifungal market because cryptococcal meningitis is a leading cause of death among people with advanced HIV disease and an important opportunistic infection in transplant recipients and other immunocompromised patients. Published global burden estimates have placed cryptococcal meningitis at roughly 152,000 annual cases and 112,000 deaths among people with HIV, underscoring a persistent need for faster diagnosis, safer induction therapy, and reliable access to essential antifungal drugs.

For pharmaceutical and antifungal therapy vendors, market opportunity is shaped by guideline-driven care pathways. Standard cryptococcosis treatment depends on induction, consolidation, and maintenance therapy using amphotericin B formulations, flucytosine, and fluconazole, with the World Health Organization endorsing simplified liposomal amphotericin B-based regimens where feasible. Competitive advantage will come from improving tolerability, expanding supply of flucytosine and liposomal amphotericin B, supporting antifungal stewardship, and aligning access programs with high-burden settings.

Transformative Shifts in the Treatment Landscape

The cryptococcosis treatment landscape is shifting from prolonged, toxicity-prone inpatient regimens toward shorter, evidence-based induction approaches that can improve adherence and reduce hospital burden. The AMBITION-cm trial demonstrated that a single high dose of liposomal amphotericin B, combined with flucytosine and fluconazole, was non-inferior to the traditional 7-day amphotericin B deoxycholate regimen for HIV-associated cryptococcal meningitis and had fewer serious adverse events, influencing global cryptococcal meningitis treatment strategies.

At the same time, demand is being reshaped by earlier cryptococcal antigen screening among people with advanced HIV, expanded transplant programs, and greater recognition of non-HIV cryptococcosis. The market is also moving toward integrated antifungal supply planning, because treatment outcomes depend not only on drug efficacy but also on diagnostic confirmation, lumbar puncture capacity, management of raised intracranial pressure, renal and hematologic monitoring, and long-term fluconazole maintenance therapy.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence cryptococcosis treatment through earlier risk identification, optimized clinical workflows, and better forecasting of antifungal demand. AI-enabled electronic health record models can flag patients with advanced HIV, low CD4 counts, transplant immunosuppression, hematologic malignancy, prolonged corticosteroid exposure, or persistent neurologic symptoms for cryptococcal antigen testing and urgent evaluation. These tools can support earlier intervention, although they require clinical validation, governance, data privacy safeguards, and bias monitoring before broad deployment.

For pharmaceutical partners, AI can strengthen pharmacovigilance, supply chain resilience, and clinical development. Machine learning can help detect adverse event patterns linked to amphotericin B nephrotoxicity or flucytosine-related cytopenias, forecast regional demand for liposomal amphotericin B and fluconazole, and identify trial sites with high unmet need. Generative and predictive models may also accelerate antifungal discovery, but regulatory-grade evidence, transparent datasets, and stewardship safeguards remain essential.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific presents a mixed profile, with advanced treatment infrastructure in Japan, Australia, and South Korea and substantial unmet need in India and parts of Southeast Asia where advanced HIV disease, delayed diagnosis, and laboratory access gaps remain important. India's large HIV treatment network, expanding tertiary care base, and rising number of immunocompromised patients make access to cryptococcal antigen testing, amphotericin B formulations, flucytosine, and fluconazole central to improving outcomes. North America benefits from strong infectious disease networks, transplant medicine, advanced diagnostics, and access to liposomal amphotericin B, while care is increasingly focused on rapid diagnosis and management of immunocompromised populations beyond HIV, including solid organ transplant, oncology, and biologic therapy patients.

Latin America has meaningful demand across Brazil and Mexico, where HIV programs and tertiary care hospitals support diagnosis but access to flucytosine and liposomal amphotericin B can be uneven across public and private settings. Europe is characterized by guideline-led treatment, robust hospital systems, reimbursement pathways, and specialized infectious disease care, although migration, oncology, intensive care, and transplant populations sustain clinical need for cryptococcosis treatment and long-term antifungal monitoring.

The Middle East is influenced by expanding tertiary care, transplant services, and GCC health investment, creating demand for hospital-based protocols and premium antifungal formulations. Africa remains the highest-burden region for HIV-associated cryptococcal meningitis, with public health agencies consistently identifying cryptococcal disease as a major cause of mortality among people with advanced HIV. In African markets, the greatest treatment gains are linked to cryptococcal antigen screening, reliable amphotericin and flucytosine availability, lumbar puncture services, electrolyte and renal monitoring, and implementation of WHO-recommended cryptococcosis treatment regimens.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, cryptococcosis treatment demand is linked to HIV program maturity, laboratory access, referral pathways, and antifungal procurement capacity, with urban referral centers often better equipped than rural facilities to deliver induction therapy and monitor amphotericin-related toxicity. The GCC is advancing specialized infectious disease, oncology, and transplant care, creating demand for premium antifungal formulations, hospital-based treatment protocols, and integrated diagnostics across high-acuity medical centers.

The European Union supports a mature treatment environment through harmonized regulatory standards, antimicrobial stewardship, strong hospital systems, and clinical guideline adoption, while BRICS markets are pivotal because they combine large patient populations, expanding healthcare infrastructure, high HIV or immunocompromised patient volumes in several member countries, and persistent access gaps. G7 countries generally lead in diagnostic availability, clinical trial capacity, pharmacovigilance, and reimbursement for liposomal amphotericin B, supporting adoption of evidence-based cryptococcal meningitis therapy and short-course induction approaches.

NATO member markets overlap significantly with high-income health systems that maintain hospital readiness, infectious disease expertise, and coordinated medical supply planning, although access and reimbursement still vary by country. Across ASEAN, GCC, the European Union, BRICS, G7, and NATO, the defining commercial issue is not only clinical need but also whether procurement, reimbursement, guideline implementation, and specialist capacity ensure consistent access to amphotericin B, flucytosine, and fluconazole.

Key Country Insights Across Major Cryptococcosis Treatment Markets

The United States and Canada represent high-value cryptococcosis treatment markets driven by advanced HIV care, transplant medicine, oncology, biologic immunosuppression, rapid diagnostics, and access to infectious disease specialists, with continued emphasis on toxicity management and real-world safety monitoring. Mexico and Brazil show expanding need supported by large public health systems and HIV care networks, but differences in regional procurement, hospital referral access, flucytosine availability, and specialist coverage can affect consistency in cryptococcal meningitis therapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from strong hospital systems, reimbursement frameworks, microbiology capacity, and guideline-based antifungal use, while Russia presents demand shaped by HIV burden, tertiary care capacity, regional healthcare variation, and procurement variability. China and India are central to Asia-Pacific demand because of large patient bases, expanding diagnostic infrastructure, growing transplant and oncology services, and rising immunocompromised populations, although access to flucytosine and liposomal amphotericin B remains an important determinant of outcomes.

Japan, Australia, and South Korea are advanced markets with high standards for hospital care, diagnostics, intensive monitoring, and antifungal safety oversight. These countries are positioned to adopt optimized cryptococcosis treatment regimens, real-world evidence programs, pharmacovigilance systems, and AI-enabled clinical decision support while maintaining strong expectations for clinical validation and stewardship.

Actionable Recommendations for Antifungal Industry Leaders

Industry vendors should prioritize reliable access to WHO-aligned antifungal regimens, especially liposomal amphotericin B, flucytosine, and fluconazole, while supporting local procurement models in high-burden countries. Organizations can differentiate by pairing drug supply with clinical education on induction therapy, renal monitoring, electrolyte replacement, cytopenia monitoring, therapeutic sequencing, lumbar puncture access, and management of raised intracranial pressure.

Strategic investment should focus on evidence generation, including real-world outcomes for short-course liposomal amphotericin B regimens, safety monitoring in diverse populations, and implementation research in resource-constrained settings. Partnerships with HIV programs, transplant centers, diagnostic manufacturers, public health agencies, and ministries of health can expand screening-to-treatment pathways, strengthen antifungal stewardship, and reduce preventable cryptococcal meningitis mortality.

Research Methodology

This executive summary is based on triangulation of peer-reviewed clinical evidence, international treatment guidelines, public health burden estimates, regulatory knowledge, and established infectious disease practice standards. Key reference points include WHO guidance for advanced HIV disease and cryptococcal disease, clinical trial evidence supporting liposomal amphotericin B-based induction therapy, and widely recognized treatment principles involving amphotericin B, flucytosine, and fluconazole.

The analysis applies a market-oriented lens to clinical data, evaluating disease burden, treatment access, regional health infrastructure, procurement dynamics, reimbursement factors, specialist availability, diagnostic readiness, and adoption barriers. Insights are structured to support SEO relevance for cryptococcosis treatment, cryptococcal meningitis therapy, antifungal drugs, amphotericin B, liposomal amphotericin B, flucytosine, fluconazole, cryptococcal antigen screening, and opportunistic infection management.

Conclusion

The cryptococcosis treatment market is entering a more evidence-driven phase as shorter liposomal amphotericin B regimens, cryptococcal antigen screening, and integrated HIV care reshape treatment expectations. Despite advances, preventable mortality remains high where diagnostics, flucytosine, amphotericin formulations, lumbar puncture services, and skilled clinical management are limited.

Pharmaceutical and antifungal therapy vendors that combine clinically proven therapies with access strategies, pharmacovigilance, stewardship, and implementation partnerships will be best positioned to address unmet need. The strongest opportunities will come from aligning innovation with practical delivery in high-burden regions and specialized immunocompromised care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cryptococcosis Treatment Market, by Drug Class

  • 7.1. Azoles
    • 7.1.1. Fluconazole
    • 7.1.2. Posaconazole
    • 7.1.3. Voriconazole
  • 7.2. Flucytosine
  • 7.3. Polyenes
    • 7.3.1. Amphotericin B Deoxycholate
    • 7.3.2. Liposomal Amphotericin B

8. Cryptococcosis Treatment Market, by Administration Route

  • 8.1. Intravenous
    • 8.1.1. Central Line
    • 8.1.2. Peripheral
  • 8.2. Oral
    • 8.2.1. Suspension
    • 8.2.2. Tablet

9. Cryptococcosis Treatment Market, by Patient Type

  • 9.1. HIV Infected
  • 9.2. Non-HIV Infected
    • 9.2.1. Immunocompetent
    • 9.2.2. Transplant Patients

10. Cryptococcosis Treatment Market, by Therapy Phase

  • 10.1. Induction Therapy
  • 10.2. Consolidation Therapy
  • 10.3. Maintenance Therapy

11. Cryptococcosis Treatment Market, by End User

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialist Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cryptococcosis Treatment Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Cryptococcosis Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cryptococcosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Astellas Pharma Inc.
  • 17.2. Aurobindo Pharma Limited
  • 17.3. Bausch Health Companies Inc.
  • 17.4. Cipla Limited
  • 17.5. Dr. Reddy's Laboratories Limited
  • 17.6. Gilead Sciences, Inc.
  • 17.7. Lupin Limited
  • 17.8. Pfizer Inc.
  • 17.9. Sun Pharmaceutical Industries Limited
  • 17.10. Teva Pharmaceutical Industries Ltd.
  • 17.11. Viatris Inc.
  • 17.12. Xellia Pharmaceuticals ApS
  • 17.13. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POSACONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POSACONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POSACONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VORICONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VORICONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VORICONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLUCYTOSINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FLUCYTOSINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FLUCYTOSINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POLYENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV INFECTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV INFECTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV INFECTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-HIV INFECTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-HIV INFECTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-HIV INFECTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 321. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 322. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 323. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 325. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 326. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 334. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 335. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 336. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 338. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 339. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 345. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 346. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 347. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 348. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 349. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 351. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2018-2032 (USD MILLION)
  • TABLE 352. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 354. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY CRYPTOCOCCOSIS TR